Vertebral, Subclavian, Brachiocephalic, and Unusual Carotid/Cervical Arterial Conditions

34.1Separate the uncommon lanes first

The first discipline in managing uncommon supra-aortic and cervical arterial disease is to resist collapsing every lesion into a familiar carotid stenosis template. Vertebral artery stenosis, subclavian stenosis or occlusion, brachiocephalic disease, cervical artery dissection, and large-vessel vasculitis each have different mechanisms of harm, different evidence bases, and different thresholds for intervention. Contemporary European and US frameworks explicitly place vertebral, subclavian, and brachiocephalic decisions within extracranial cerebrovascular and peripheral arterial disease guidance, but they do not make these bedsides problems interchangeable. SVS 2021 · ESC 2017 · ACC/AHA 2011

For vertebral artery disease, the clinical lane is posterior-circulation ischemia and response to medical therapy, not stenosis percentage in isolation. Randomized and pooled data have not established vertebral stenting as superior to medical therapy for stroke prevention, so the vascular surgeon should treat “symptomatic vertebral stenosis” as a selective-intervention diagnosis rather than as an automatic procedural indication. Percutaneous transluminal angioplasty 2026 · Stenting symptomatic vertebral 2019 · Stenting versus medical 2015

Subclavian disease has a different bedside logic. The lesion becomes clinically important when it explains a concrete syndrome: arm claudication, coronary-subclavian steal in a patient with prior LIMA coronary bypass, or vertebrobasilar steal symptoms. The treatment question is therefore not simply whether an angiographic narrowing exists, but whether the narrowing accounts for a symptom complex that an intervention can plausibly relieve, recognizing that the evidence base remains dominated by small trials and observational data. Angioplasty versus stenting 2022

Brachiocephalic disease should be deliberately separated from both carotid bifurcation disease and isolated subclavian disease. The 2023 ESVS carotid and vertebral guidance treats innominate disease as its own supra-aortic decision lane, requiring individualized assessment of cerebral and upper-extremity ischemia rather than direct transplantation of carotid intervention thresholds. Editor's Choice European 2023

Cervical artery dissection is another distinct lane. The surgeon’s first task is to classify the dissection by location and bleeding context: extracranial ischemic dissection, intracranial nonhemorrhagic dissection, or intracranial dissection with hemorrhage. Antithrombotic choice should then be anchored to the dissection location, mechanism of ischemia, and bleeding-risk profile, rather than to a reflexive preference for either anticoagulation or antiplatelet therapy. Treatment Outcomes Cervical 2024 · ESO guideline management 2021

Large-vessel vasculitis with cervical or supra-aortic involvement belongs beside, but not inside, the atherosclerotic algorithm. Giant cell arteritis and Takayasu arteritis require a vasculitis framework for imaging, immunosuppression, and revascularization judgment; the key surgical teaching point is that revascularization decisions should be made in the context of systemic inflammatory disease rather than treated as ordinary plaque disease. GCA 2021

34.2Imaging defines the lane

Imaging should answer a management question, not merely display an abnormal artery. In vertebral, subclavian, and brachiocephalic disease, the report should help the team decide whether the patient has an extracranial supra-aortic lesion, an intracranial vertebrobasilar lesion, a lesion explaining upper-extremity or coronary-subclavian steal physiology, or a brachiocephalic pattern requiring individualized cerebral and arm-ischemia assessment. This distinction matters because extracranial vertebral disease, intracranial stenosis, subclavian disease, and innominate disease sit in different evidence lanes. Editor's Choice European 2023 · SVS 2021 · ESC 2017

The vertebral artery must be localized as extracranial or intracranial before treatment claims are made. Extracranial vertebral disease is addressed within extracranial cerebrovascular guidance, while intracranial stenosis is informed by the SAMMPRIS and VISSIT experience, in which intracranial stenting strategies were halted early for harm or futility/harm compared with medical therapy. That separation should be visible in the operative conference note. SVS 2021 · VISSIT · 2015 · SAMMPRIS 2011

In subclavian disease, imaging interpretation should be tied to the symptom being investigated. The same anatomic lesion may be incidental, may explain arm claudication, may threaten a LIMA graft through coronary-subclavian steal, or may contribute to vertebrobasilar steal symptoms. A useful imaging conclusion therefore states both the lesion and the clinical syndrome it is being asked to explain. Angioplasty versus stenting 2022

In brachiocephalic disease, imaging should define the full supra-aortic territory at risk. The decision is not reducible to carotid stenosis severity; it must account for both cerebral and upper-extremity ischemia. This is the practical reason to label innominate disease separately in the problem list and to avoid carrying over carotid bifurcation thresholds without reconsideration. Editor's Choice European 2023

For cervical artery dissection, imaging classification changes the treatment conversation. A patient with extracranial ischemic dissection is not the same as a patient with intracranial dissection and hemorrhage, and antithrombotic choice must be made with that distinction explicit. The imaging report and clinical assessment should therefore identify dissection location, ischemic mechanism, and bleeding risk before the team chooses antiplatelet or anticoagulant therapy. Treatment Outcomes Cervical 2024 · ESO guideline management 2021

For unusual carotid or cervical arterial presentations, imaging should also identify whether the disease is atherosclerotic, dissecting, or inflammatory. Large-vessel vasculitis has its own guideline framework, and the presence of giant cell arteritis or Takayasu arteritis changes the sequence of medical and procedural planning. The surgeon should not allow an impressive cervical-artery stenosis to obscure the systemic diagnosis. GCA 2021

34.3Treatment claims stay bounded

Medical therapy remains the default reference point for many patients with vertebral artery disease because the procedural evidence is narrow. For symptomatic vertebral stenosis, a 2026 Cochrane review found no clear randomized-evidence benefit of stenting over medical therapy, and pooled data through 2019 similarly do not establish stenting as superior for stroke prevention. The trainee should therefore present vertebral stenting as a selective option considered after careful symptom attribution and medical-therapy assessment, not as the standard response to an anatomic stenosis. Percutaneous transluminal angioplasty 2026 · Stenting symptomatic vertebral 2019

The VAST trial provides the index randomized vertebral-stenting reference point, but its small recruited sample limits precision. Intracranial stenting evidence is even more cautionary: SAMMPRIS was halted early for harm in the stenting arm, and VISSIT was stopped early for futility/harm. In practice, this means that an intracranial vertebrobasilar lesion should trigger a different risk discussion from an extracranial origin lesion. Stenting versus medical 2015 · VISSIT · 2015 · SAMMPRIS 2011

Subclavian intervention is most defensible when the target syndrome is concrete and clinically meaningful. Angioplasty and stenting can resolve arm claudication, coronary-subclavian steal after LIMA bypass, or vertebrobasilar steal symptoms, but the evidence base is limited by small trials and observational data. The operative indication should therefore name the symptom being treated and avoid implying proven stroke-prevention benefit beyond the supported syndrome. Angioplasty versus stenting 2022

For cervical artery dissection, antithrombotic treatment should be framed as equipoise when the patient has acute symptomatic extracranial dissection. CADISS randomized adults with extracranial carotid or vertebral dissection to antiplatelet therapy or anticoagulation for the initial three-month period, and the final analysis found a low 12-month ipsilateral stroke rate without a statistically significant difference between strategies. TREAT-CAD adds a contemporary randomized non-inferiority trial layer comparing aspirin with anticoagulation, reinforcing that the choice should be individualized rather than dogmatic. ESO guideline management 2021 · Treat Cad · 2021 · CADISS randomized trial 2019

Secondary prevention should not be underemphasized while the team debates procedures. Patients with prior dissection-associated stroke or TIA still require the standard stroke-prevention envelope: antithrombotic planning, blood-pressure management, statin therapy when appropriate to the vascular context, and lifestyle intervention. For stable atherosclerotic vascular disease, COMPASS provides the contemporary trial reference point for discussions of more intensive antithrombotic strategies, but vertebral, subclavian, and brachiocephalic decisions must be framed within the broader atherosclerotic population rather than as proven lesion-specific subgroup mandates. Treatment Outcomes Cervical 2024 · AHA 2021 · COMPASS 2017

When unusual cervical carotid disease enters the chapter through carotid revascularization choices, the evidence base must be identified precisely. ICSS and EVA-3S are symptomatic carotid stenosis stent-versus-endarterectomy trial anchors; ACT-1 and ACST-2 inform asymptomatic carotid stenosis comparisons; ROADSTER and ROADSTER 2 support the TCAR evidence lineage; and the SVS VQI TCAR Surveillance Project supplies contemporary registry comparisons among TCAR, transfemoral stenting, and endarterectomy. None of these should be used to justify intervention for vertebral, subclavian, or brachiocephalic disease without a separate lesion-specific rationale. One-year outcomes after 2022 · Second Asymptomatic Carotid 2021 · Randomized Trial Stent 2016 · Long-term outcomes after 2015 · ROADSTER 2015 · Endarterectomy versus Angioplasty 2008 · SVS 2024

34.4Clinical integration, follow-up, and evidence boundaries

A practical treatment conference for these patients should begin with four questions: what syndrome is present, which artery and segment explain it, whether the lesion is atherosclerotic, dissecting, or inflammatory, and what evidence lane applies. This structure keeps the team from offering a familiar operation for an unfamiliar problem and forces symptom attribution before procedural enthusiasm. SVS 2021 · ESC 2017 · ACC/AHA 2011

Follow-up after medical or procedural treatment should track the original clinical failure mode. For vertebral disease, the concern is recurrent posterior-circulation ischemia and whether symptoms persist despite medical therapy; for subclavian disease, the relevant endpoints are relief or recurrence of arm claudication, coronary-subclavian steal, or vertebrobasilar steal symptoms; for brachiocephalic disease, surveillance must remain individualized to cerebral and upper-extremity ischemia rather than a single carotid-style stenosis threshold. Editor's Choice European 2023 · Percutaneous transluminal angioplasty 2026 · Angioplasty versus stenting 2022

In dissection follow-up, the bedside message is reassurance without complacency. CADISS reported a low 12-month ipsilateral stroke rate, with all recurrent strokes occurring in patients who initially presented with stroke and none in local-symptom-only presentations. That finding should temper escalation in low-risk presentations while reminding the team that patients presenting with stroke may represent a higher-risk subset. CADISS randomized trial 2019

The failure mode in intracranial vertebrobasilar atherosclerotic disease is different from extracranial origin disease. Because SAMMPRIS and VISSIT reinforced caution about intracranial stenting, a patient with intracranial stenosis should not be counseled as though the team is simply extending extracranial vertebral-origin practice. This distinction is especially important when symptoms are severe and the temptation to “do something” is high. VISSIT · 2015 · SAMMPRIS 2011

Inflammatory cervical-arterial disease requires longitudinal coordination beyond the vascular procedure. The ACR/Vasculitis Foundation framework for giant cell arteritis and Takayasu arteritis places imaging, immunosuppression, and revascularization inside a disease-specific plan. In surgical practice, that means the operative note, follow-up plan, and referral pattern should all reflect the vasculitis diagnosis rather than describing only the treated arterial segment. GCA 2021

The chapter’s evidence boundary should be explicit for trainees: guidelines frame the lanes, but many specific decisions are supported by limited randomized data, observational series, registry analyses, or extrapolation from broader atherosclerotic and stroke-prevention populations. Good care therefore depends on precise diagnosis, conservative wording of procedural benefit, and follow-up tied to the patient’s actual syndrome. Treatment Outcomes Cervical 2024 · AHA 2021 · Percutaneous transluminal angioplasty 2026 · Angioplasty versus stenting 2022 · COMPASS 2017